Abstract
In Belgium more than 17 % of the invasive pneumococci are not susceptible to penicillin, and more than 38 % not to macrolides. The most prevalent mechanism of macrolide resistance in Europe is modification of the drug target site leading to cross-resistance to lincosamides and group B streptogramines (MLSB resistance).Telithromycin is the first antibiotic of the family of ketolides, which differ from erythromycin by having a 3-keto group instead of the neutral sugar L-cladinose.We tested the susceptibility of 637 pneumococci, recently isolated from patients in Belgium, to telithromycin and five other antibiotics. Data generated by this study show that telithromycin inhibits 98.4 % of pneumococci at a breakpoint concentration of 1 mg/L in spite of a high percentage ( >30 %) of strains with the MLSB constitutive type of resistance. Susceptibilities to the five comparator drugs were : penicillin (81.8 %), tetracycline (67.0 %), levofloxacin (98.9 %), erythromycin (61.5 %) and clindamycin (66.6 %). Consequently telithromycin looks to have considerable potential for the empiric treatment of community-acquired respiratory tract infections.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
